Madrigal Pharmaceuticals (YDO1) Stock Statistics & Valuation Metrics

Madrigal Pharmaceuticals has a market cap or net worth of CHF9.56B. The enterprise value is $11.64B.

Madrigal Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Madrigal Pharmaceuticals’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -31.58%.

The current PE Ratio of Madrigal Pharmaceuticals is ―. Madrigal Pharmaceuticals’s PEG ratio is 1.10.

In the last 12 months, Madrigal Pharmaceuticals had revenue of 958.40M and earned -288.28M in profits. Earnings per share was -12.85.

In the last 12 months, operating cash flow was -268.10M and capital expenditures -4.32M, giving a free cash flow of -272.41M billion.

Madrigal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Madrigal Pharmaceuticals upcoming earnings date is Aug 11, 2026, Before Open (Confirmed).

Madrigal Pharmaceuticals as a current ratio of 4.01, with Debt / Equity ratio of 63.91%

In the past 12 months, Madrigal Pharmaceuticals has paid 0.00 in taxes.

Madrigal Pharmaceuticals EV to EBITDA ratio is -49.99, with an EV/FCF ratio of -69.57.

Madrigal Pharmaceuticals has CHF817.93M in cash and marketable securities with CHF347.31M in debt, giving a net cash position of CHF470.62M billion.

Gross margin is 93.07%, with operating margin of -31.31%, and net profit margin of -30.08%.

The average price target for Madrigal Pharmaceuticals is CHF548.09, which is 11.43% higher than the current price. The consensus rating is Strong Buy